Eli Lilly Purchases Nexus Pharmaceutical Injectables Manufacturing Plant
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
Riding the momentum of its digital platform LillyDirect that will sell certain drugs directly to consumers with a prescription for conditions such as diabetes, obesity, and migraine,1 Eli Lilly and Company has acquired a Pleasant Prairie, WI manufacturing facility from Nexus Pharmaceuticals, a sterile manufacturer in the pharma sector.2
The deal is expected to grow Lilly's global parenteral (injectable) product manufacturing network, while adding more demand for the Big Pharma company's medications. Production at this newly acquired plant could commence as early as the end of 2025.
“The acquisition of this state-of-the-art facility underscores our unwavering commitment to growth and innovation, and we look forward to welcoming talented new Nexus colleagues to Lilly from the Pleasant Prairie facility,” said Edgardo Hernandez, EVP and president, Lilly manufacturing. “We are investing boldly to serve our patients, to meet product demand and to build capabilities for our robust pipeline of the future.”
Being that this specific facility does not offer contract manufacturing services, it will be able to invest additional time toward manufacturing for its customers; Nexus also expressed its approval of the deal.
“We are excited Lilly is continuing our family’s mission of providing lifesaving medications to those who need them most,” noted Usman Ahmed, the company’s president and CEO. “This milestone is a testament to the dedication of our Nexus employees in building a best-in-class injectable manufacturing facility. The combination of our teams and infrastructure with Lilly’s global platform will benefit patients all over the world.”
References
1. Eli Lilly Announces New Telehealth, Home Delivery Option for Popular Weight Loss Drug. Pharmaceutical Commerce. January 5, 2024. Accessed April 25, 2024. https://www.pharmaceuticalcommerce.com/view/eli-lilly-announces-new-telehealth-home-delivery-option-for-popular-weight-loss-drug
2. Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals. Eli Lilly and Company. April 22, 2024. Accessed April 25, 2024. https://investor.lilly.com/news-releases/news-release-details/lilly-acquires-new-injectable-medicine-manufacturing-facility
